Karham Kim

The optimal chemotherapeutic regimen in D2-resected locally advanced gastric cancer: a propensity score-matched analysis

Y. K. Park, Ju-Seog Lee, E. Hwang, 2017, Oncotarget.

Different protein expression associated with chemotherapy response in oropharyngeal cancer according to HPV status

J. Hwang, I. Chung, M. Ki, 2014, BMC Cancer.

The role of interim FDG PET-CT after induction chemotherapy as a predictor of concurrent chemoradiotherapy efficacy and prognosis for head and neck cancer

Sae-Ryung Kang, J. Hwang, I. Chung, 2017, European Journal of Nuclear Medicine and Molecular Imaging.

A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer

J. Hwang, I. Chung, Young-Kyu Park, 2016, Cancer Chemotherapy and Pharmacology.

A Randomized, Double-Blind Pilot Study of Dose Comparison of Ramosetron to Prevent Chemotherapy-Induced Nausea and Vomiting

J. Hwang, Seongwook Jeong, I. Chung, 2015, BioMed research international.

Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer

E. Hwang, J. Hwang, I. Chung, 2013, BMC Cancer.

FGFR4 Arg388 Is Correlated with Poor Survival in Resected Colon Cancer Promoting Epithelial to Mesenchymal Transition

M. Shin, H. Kim, J. Hwang, 2016, Cancer research and treatment : official journal of Korean Cancer Association.

Role of depth of response and MTHFR genotype as predictors of fluorouracil rechallenge therapy for refractory metastatic colorectal cancer.

M. Shin, H. Kim, J. Hwang, 2017, Oncology letters.

Role of depth of response and MTHFR genotype as predictors of fluorouracil rechallenge therapy for refractory metastatic colorectal cancer.

M. Shin, H. Kim, J. Hwang, 2017, Oncology letters.